Literature DB >> 25828473

Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.

Dragana Kopanja1, Akshay Pandey1, Megan Kiefer1, Zebin Wang1, Neha Chandan1, Janai R Carr2, Roberta Franks3, Dae-Yeul Yu4, Grace Guzman5, Ajay Maker6, Pradip Raychaudhuri7.   

Abstract

BACKGROUND & AIMS: Overexpression of FoxM1 correlates with poor prognosis in hepatocellular carcinoma (HCC). Moreover, the Ras-signaling pathway is found to be ubiquitously activated in HCC through epigenetic silencing of the Ras-regulators. We investigated the roles of FoxM1 in Ras-driven HCC, and on HCC cells with stem-like features.
METHODS: We employed a transgenic mouse model that expresses the oncogenic Ras in the liver. That strain was crossed with a strain that harbor floxed alleles of FoxM1 and the MxCre gene that allows conditional deletion of FoxM1. FoxM1 alleles were deleted after development of HCC, and the effects on the tumors were analyzed. Also, FoxM1 siRNA was used in human HCC cell lines to determine its role in the survival of the HCC cells with stem cell features.
RESULTS: Ras-driven tumors overexpress FoxM1. Deletion of FoxM1 inhibits HCC progression. There was increased accumulation of reactive oxygen species (ROS) in the FoxM1 deleted HCC cells. Moreover, FoxM1 deletion caused a disproportionate loss of the CD44+ and EpCAM+ HCC cells in the tumors. We show that FoxM1 directly activates expression of CD44 in human HCC cells. Moreover, the human HCC cells with stem cell features are addicted to FoxM1 for ROS-regulation and survival.
CONCLUSION: Our results provide genetic evidence for an essential role of FoxM1 in the progression of Ras-driven HCC. In addition, FoxM1 is required for the expression of CD44 in HCC cells. Moreover, FoxM1 plays a critical role in the survival of the HCC cells with stem cell features by regulating ROS. Published by Elsevier B.V.

Entities:  

Keywords:  FoxM1; Liver cancer cells with stem cell features; Ras-driven liver cancer

Mesh:

Substances:

Year:  2015        PMID: 25828473      PMCID: PMC4508215          DOI: 10.1016/j.jhep.2015.03.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  32 in total

1.  FoxM1 is required for execution of the mitotic programme and chromosome stability.

Authors:  Jamila Laoukili; Matthijs R H Kooistra; Alexandra Brás; Jos Kauw; Ron M Kerkhoven; Ashby Morrison; Hans Clevers; René H Medema
Journal:  Nat Cell Biol       Date:  2005-01-16       Impact factor: 28.824

2.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Gender-dependent hepatic alterations in H-ras12V transgenic mice.

Authors:  Ai-Guo Wang; Hyung-Bae Moon; Mi-Ran Lee; Chae Young Hwang; Ki-Sun Kwon; Seong-Lan Yu; Yong-Sung Kim; Mirang Kim; Jin-Man Kim; Sang-Keun Kim; Tae-Hoon Lee; Eun-Yi Moon; Dong-Seok Lee; Dae-Yeul Yu
Journal:  J Hepatol       Date:  2005-06-02       Impact factor: 25.083

4.  Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis.

Authors:  Jianfei Xue; Xia Lin; Wen-Tai Chiu; Yao-Hui Chen; Guanzhen Yu; Mingguang Liu; Xin-Hua Feng; Raymond Sawaya; René H Medema; Mien-Chie Hung; Suyun Huang
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  Steatosis induced by the accumulation of apolipoprotein A-I and elevated ROS levels in H-ras12V transgenic mice contributes to hepatic lesions.

Authors:  Ai-Guo Wang; Hyung-Bae Moon; Jung-Il Chae; Jin-Man Kim; Ye-Eun Kim; Dae-Yeul Yu; Dong-Seok Lee
Journal:  Biochem Biophys Res Commun       Date:  2011-05-12       Impact factor: 3.575

6.  FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors.

Authors:  Zebin Wang; Hyun Jung Park; Janai R Carr; Yi-ju Chen; Yu Zheng; Jing Li; Angela L Tyner; Robert H Costa; Srilata Bagchi; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2011-04-20       Impact factor: 12.701

7.  Induction of human epithelial stem/progenitor expansion by FOXM1.

Authors:  Emilios Gemenetzidis; Daniela Elena-Costea; Eric K Parkinson; Ahmad Waseem; Hong Wan; Muy-Teck Teh
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

8.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.

Authors:  Vladimir V Kalinichenko; Michael L Major; Xinhe Wang; Vladimir Petrovic; Joseph Kuechle; Helena M Yoder; Margaret B Dennewitz; Brian Shin; Abhishek Datta; Pradip Raychaudhuri; Robert H Costa
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

9.  Deregulation of FoxM1b leads to tumour metastasis.

Authors:  Hyun Jung Park; Galina Gusarova; Zebin Wang; Janai R Carr; Jing Li; Ki-Hyun Kim; Jin Qiu; Yoon-Dong Park; Peter R Williamson; Nissim Hay; Angela L Tyner; Lester F Lau; Robert H Costa; Pradip Raychaudhuri
Journal:  EMBO Mol Med       Date:  2010-12-17       Impact factor: 12.137

10.  Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells.

Authors:  Zhongqiu Xie; Guixiang Tan; Miao Ding; Difei Dong; Tuanhui Chen; Xiangxian Meng; Xiaoqin Huang; Yongjun Tan
Journal:  Nucleic Acids Res       Date:  2010-08-11       Impact factor: 16.971

View more
  33 in total

1.  Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.

Authors:  Vaibhav Chand; Akshay Pandey; Dragana Kopanja; Grace Guzman; Pradip Raychaudhuri
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

2.  Pluripotency Transcription Factors and Metabolic Reprogramming of Mitochondria in Tumor-Initiating Stem-like Cells.

Authors:  Keigo Machida
Journal:  Antioxid Redox Signal       Date:  2018-04-10       Impact factor: 8.401

3.  p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.

Authors:  Dragana Kopanja; Shuo Huang; Mohamed Rizwan Haroon Al Raheed; Grace Guzman; Pradip Raychaudhuri
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

Review 4.  Forkhead Box Transcription Factors: Double-Edged Swords in Cancer.

Authors:  Maria Castaneda; Petra den Hollander; Sendurai A Mani
Journal:  Cancer Res       Date:  2022-06-06       Impact factor: 13.312

5.  FOXM1 is a therapeutic target for high-risk multiple myeloma.

Authors:  C Gu; Y Yang; R Sompallae; H Xu; V S Tompkins; C Holman; D Hose; H Goldschmidt; G Tricot; F Zhan; S Janz
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

Review 6.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

7.  Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer.

Authors:  Shou-Hua Wang; Fei Ma; Zhao-Hui Tang; Xiao-Cai Wu; Qiang Cai; Ming-Di Zhang; Ming-Zhe Weng; Di Zhou; Jian-Dong Wang; Zhi-Wei Quan
Journal:  J Exp Clin Cancer Res       Date:  2016-10-03

8.  Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.

Authors:  Huiting Su; Bing Li; Lan Zheng; Haixia Wang; Liping Zhang
Journal:  Oncotarget       Date:  2016-07-26

9.  Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.

Authors:  DeJie Wang; Guohui Hu; Ying Du; Cheng Zhang; Quqin Lu; Nonghua Lv; Shiwen Luo
Journal:  J Exp Clin Cancer Res       Date:  2017-02-02

Review 10.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.